Triazine Scaffold Research Articles

Synthesis and Properties of Tris(3‐Pyrrolyl BODIPY) on 1, 3, 5‐Triazine Scaffold

AbstractTris(3‐pyrrolyl BODIPY) on 1,3,5‐triazine scaffold was synthesized over a sequence of steps starting from commercially available cyanuric chloride. The cyanuric chloride was reacted with p‐hydroxy benzaldehyde to afford 1,3,5‐triazine tris(p‐oxybenzaldehyde) which was then reacted with excess pyrrole under acid catalyzed conditions to afford 1,3,5‐triazine‐tris(meso‐p‐oxyphenyl dipyrromethane). Subsequent in situ oxidation of this compound with DDQ to obtain tris(meso‐oxyphenyldipyrromethene) which was then treated with pyrrole followed by the addition of Et3N/BF3 ⋅ OEt2 afforded fluorescent tris(3‐pyrrolyl BODIPY). For comparison, tris(BODIPY) on the triazine scaffold was prepared by oxidizing tris(meso‐oxyphenyldipyrromethane) with DDQ followed by complexation with BF3 ⋅ OEt2. Both compounds were thoroughly characterized and studied by various experimental and theoretical methods. Absorption, steady state fluorescence, time‐resolved fluorescence, and transient‐absorption studies revealed that in tris(3‐pyrrolyl BODIPY), excitonic interactions between two of the three 3‐pyrrolyl BODIPY units resulted in a hypsochromic shift in spectral bands, reducing the quantum yield and singlet state lifetime whereas tris(BODIPY) did not show such excitonic interactions. DFT studies helped in understanding the excitonic interactions in tris(3‐pyrrolyl BODIPY). The tris(3‐pyrrolyl BODIPY) was fluorescent both in solution and solid state. The viscosity studies indicated that the fluorescence of tris(3‐pyrrolyl BODIPY) increases significantly with solvent viscosity, suggesting its potential for measuring cellular viscosity during physiological processes.

A Pharmacological Overview and Recent Patent of Triazine Scaffold in Drug Development: A Review

<p>The triazine moiety holds a special and very important position in the field of medicinal chemistry owing to its enormous biological and pharmacological potential. Over eras, triazine scaffolds have been investigated for synthesizing novel molecules that may be used for the treatment of different types of pathological conditions, such as infections, cancer, inflammation etc. A vast number of lead molecules have been established from the triazine moiety. The triazine fused with numerous heterocyclic rings, such as pyrrole, benzimidazole, indole, imidazole, carbazole, etc., have formed various bicyclic with pharmacological actions. The triazines display a wide range of activities, and synthesizing various marketable medicines that hold triazine moiety has made the attention of chemists worldwide grow over the years in the moiety. In this review article, the commercially available compound containing triazine has been presented, and an attempt has been made to collect the works reported, mostly in the past decade, by numerous scientists, related to the structural differences amongst the triazine analogues giving antitumor, and antimicrobial and other activities. </p><p> The objective of this review article was to outline the current information on triazines and their derivatives with respect to their biological potential and various pharmacological activities. </p><p> The summary of this review article would be helpful and describe the function and activity of the moiety to bring up-to-date the scientists working in the direction of designing and synthesising novel lead molecules for the treatment of different types of disease with the current molecules that have been synthesized from the triazine scaffold.</p>

In-vitro Evaluation of Triazine Scaffold for Anticancer Drug Development: A Review.

The widespread importance of the synthesis and modification of anticancer agents has given rise to many numbers of medicinal chemistry programs. In this regard, triazine derivatives have attracted attention due to their remarkable activity against a wide range of cancer cells. This evaluation covers work reports to define the anticancer activity, the most active synthesized compound for the target, the SAR and, when described, the probable MOA besides similarly considered to deliver complete and target-pointed data for the development of types of anti-tumour medicines of triazine derivatives. Triazine scaffold for the development of anticancer analogues. Triazine can also relate to numerous beneficial targets, and their analogues have auspicious in-vitro and in-vivo anti-tumour activity. Fused molecules can improve efficacy, and drug resistance and diminish side effects, and numerous hybrid molecules are beneath diverse stages of clinical trials, so hybrid derivatives of triazine may offer valuable therapeutic involvement for the dealing of tumours. The objective of the recent review was to summarize the recent reports on triazine as well as its analogues with respect to its anticancer therapeutic potential. The content of the review would be helpful to update the researchers working towards the synthesis and designing of new molecules for the treatment of various types of cancer disease with the recent molecules that have been produced from the triazine scaffold. Triazine scaffolds based on 1,3,5-triazine considerably boost molecular diversity levels and enable covering chemical space in key medicinal chemistry fields.

Carbonic Anhydrase IX Targeting Mn(II)-Based Magnetic Resonance Molecular Imaging Probe for Hypoxia Tumors.

Physiological hypoxic conditions in the tumor microenvironment and consequential overexpression of carbonic anhydrase IX (CA IX) are two characteristics shared by numerous types of solid malignant tumors. Early detection with hypoxia assessment is crucial to improve the prognosis and therapy outcomes of hypoxia tumors. Herein, using acetazolamide (AZA) as a CA IX-targeting moiety, we design and synthesize an Mn(II)-based MR imaging probe (named AZA-TA-Mn) incorporating AZA and two Mn(II) chelates of Mn-TyEDTA on a rigid triazine (TA) scaffold. The per Mn relaxivity of AZA-TA-Mn is 2-fold higher than its monomeric Mn-TyEDTA, which allows it for low-dose imaging of hypoxic tumors. In a xenograft mice model of esophageal squamous cell carcinoma (ESCC), a low dosage of AZA-TA-Mn (0.05 mmol/kg) can selectively produce prolonged and stronger contrast enhancement in the tumor compared to the non-specific Gd-DTPA (0.1 mmol/kg). A competition study of co-injection of free AZA and Mn(II) probes confirms the in vivo tumor selectivity of AZA-TA-Mn, resulting in a more than 2.5-fold decreased tumor-to-muscle contrast-to-noise ratio (ΔCNR) at 60 min post-injection. MR imaging results were further supported by the quantitative analysis of Mn tissue levels, as the co-injection of free AZA resulted in significantly reduced Mn accumulation in tumor tissues. Finally, immunofluorescence staining of tissue sections confirms the positive correlation between the tumor accumulation of AZA-TA-Mn and CA IX overexpression. Hence, using CA IX as the hypoxia biomarker, our results illustrate a practical strategy for the development of novel imaging probes for hypoxic tumors.

New antiproliferative agents derived from tricyclic 3,4-dihydrobenzo[4,5]imidazo[1,2-a][1,3,5]triazine scaffold: Synthesis and pharmacological effects.

A series of novel 3,4-dihydrobenzo[4,5]imidazo[1,2-a][1,3,5]triazine (BIT) derivatives were designed and synthesized. In vitro antiproliferative activity was detected toward two human colorectal adenocarcinoma cell lines (CaCo-2 and HT-29) and one human dermal microvascular endothelial cell line (HMVEC-d). The most active compounds, namely 2-4 and 8, were further investigated to clarify the mechanism behind their biological activity. Through immunofluorescence assay, we identified the target of these molecules to be the microtubule cytoskeleton with subsequent formation of dense microtubule accumulation, particularly at the periphery of the cancer cells, as observed in paclitaxel-treated cells. Overall, these results highlight BIT derivatives as robust and feasible candidates deserving to be further developed in the search for novel potent antiproliferative microtubule-targeting agents.

Using new solvatochromic parameters to investigate dye–solvent interactions

Solvatochromic behaviours of triazine substituted dyes were evaluated using a novel approach derived from the red shift index (RsI) and associated solvation energy (ASE). These parameters were used to describe the solvation trends of the dye–solvent interactions based on their polarity changes. The concept demonstrates the effect of substituent changes on the triazine scaffold and the induced solvent polarity changes as solvated dyes go through the HOMO–LUMO (highest occupied molecular orbital-lowest uncopied molecular orbital) phases. Primarily, these phases were characterised by evaluating the wavelength of the absorption and emission spectra in different solvents, which, in conjunction with the recently reported computational approaches, provides a well-adjusted model for predicting spectra polarity changes between the dye (solute) and the solvent. Based on the results from this study, predictive polarity changes on the triazine scaffold in different solvents can be empirically monitored both in ground and excited states. Moreover, the solvatochromic parameters can be extended to evaluate the predictive behaviours of different spectra dyes.

Various Techniques for One-Pot Synthesis of 1,3,5-Triazine (s-Triazine) Derivatives: A Review

: Recent studies have shown that one-pot synthesis is a boon for triazines synthesis. One-pot processes had significant success in carrying out complex reactions under mild and eco-friendly conditions. One-pot synthesis is environmentally benign and more economical than other processes in triazines synthesis. The triazine scaffold has provided the starting key point for the design and development of pharmaceutical molecules with wide range of biomedical applications. This review highlights the various methodologies involved for one-pot synthesis of 1,3,5-triazine scaffolds.

Anticancer Potential of Triazine Scaffold: A Brief Review

Triazine is an important class of heterocyclic compounds. Triazine is a six-membered heterocyclic compound with three carbons replaced by nitrogen in the benzene ring. Triazine and its compounds exhibit a wide variety of pharmacological activity such as antifungal, anti-HIV, anticancer, antioxidant, anti-inflammatory, analgesic, antihypertensive, antiviral, antimalarial, antiprotozoal, and antibacterial. The triazine ring has been modified at different positions to generate new molecules. The structure of the new derivatives was characterized by common analytical method. Some examples of triazine compounds commonly used in rational medicine are: Ceftriaxone as an antimicrobial agent and 6-Azacytosine as an antiviral agent. The present review article enumerates on the biological potential of triazine and how it is beneficial to discover more new compounds that could be better in terms of efficacy and lesser toxicity.

Synthesis, biological activity, and in silico studies of thieno[2,3-d]pyrimidine and thieno[2,3-d]triazine derivatives

Background The chemistry of condensed heterocyclic compounds has emerged in numerous reports for their diverse biological properties and drug discovery. Pyrimidine and triazine scaffolds have been utilized as therapeutic agents in many medicinal applications. Many research groups have designed and synthesized pyrimidine moieties as they are incorporated in nucleic acid bases.Objective In this report, we have designed and synthesized a variety of 2-mercaptothieno pyrimidine and thienotriazine derivatives and 2-mercaptothienopyrimidines conjugated with sugar moiety. The newly synthesized compounds were tested for their biological activity against breast (MCF-7), liver (HepG-2), and prostate (PC-3) cancer cell lines as well as a normal cell line (human normal melanocyte, HFB4) and were also analyzed for in silico studies to determine their potential.Materials and methods A variety of 2-mercaptothienopyrimidine and thienotriazine derivatives were prepared via cyclization of ethyl 2-amino-4,5,6,7-tetrahydrobenzo[b]thiophene-3-carboxylate (1) and 2-amino-N-phenyl-4,5,6,7-tetrahydrobenzo[b]thiophene-3-carboxamide (9). Two derivatives of 2-mercaptothienopyrimidines conjugated with sugar moiety were also prepared. The products were screened for their biological activity against breast (MCF-7), liver (HepG-2), and prostate (PC-3) cancer cell lines as well as the normal cell line (human normal melanocyte, HFB4) in comparison with the known anticancer drug 5-fluorouracil using the MTT assay.Results and conclusion The results indicated that most of the tested compounds exhibited no activity against the growth of HFB4. Compounds 5, 8, 10, 12, and 14 revealed effective antiproliferative activity against MCF-7 cell lines with IC50 of 4.6, 6.2, 5.4, 7, and 3.25 µg/ml, respectively, compared with 5-fluorouracil (IC50 of 3.97 µg/ml). In the same sense, the evaluation of cytotoxic effect of the tested compounds against human liver HepG-2 cancer cell lines revealed that compounds 5, 8, 10, 12, and 14 showed cytotoxic activity close to that of the standard drug (IC50 values of 5.77±0.99, 7.23±0.98, 4.42±1.32, 7.9±0.90, and 5.1±11.28 µg/ml, respectively, vs. 4.27±0.58 µg/ml for 5-fluorouracil). Free binding energy was estimated by docking and MM-GBSA calculation. Molecular dynamics simulation followed by MM-GBSA calculation was correlated to the cytotoxic effect. Compound 14 illustrated the highest MM-GBSA value (−20.38) and the best cytotoxic effect.

New antiproliferative agents derived from tricyclic 3,4-dihydrobenzo[4,5]imidazo[1,2-a][1,3,5]triazine scaffold: synthesis and pharmacological effects

New antiproliferative agents derived from tricyclic 3,4-dihydrobenzo[4,5]imidazo[1,2-a][1,3,5]triazine scaffold: synthesis and pharmacological effects

Pyrrolo[2,1-f][1,2,4]triazine: a promising fused heterocycle to target kinases in cancer therapy.

Cancer is the second leading cause of death worldwide responsible for about 10 million deaths per year. To date several approaches have been developed to treat this deadly disease including surgery, chemotherapy, radiation therapy, hormonal therapy, targeted therapy, and synthetic lethality. The targeted therapy refers to targeting only specific proteins or enzymes that are dysregulated in cancer rather than killing all rapidly dividing cells, has gained much attention in the recent past. Kinase inhibition is one of the most successful approaches in targeted therapy. As of 30 March 2021, FDA has approved 65 small molecule protein kinase inhibitors and most of them are for cancer therapy. Interestingly, several kinase inhibitors contain one or more fused heterocycles as part of their structures. Pyrrolo[2,1-f][1,2,4]triazine is one the most interesting fused heterocycle that is an integral part of several kinase inhibitors and nucleoside drugs viz. avapritinib and remdesivir. This review articles focus on the recent advances made in the development of kinase inhibitors containing pyrrolo[2,1-f][1,2,4]triazine scaffold.

Innovative Strategies for the Construction of Diverse 1'-Modified C-Nucleoside Derivatives.

Modified C-nucleosides have proven to be enormously successful as chemical probes to understand fundamental biological processes and as small-molecule drugs for cancer and infectious diseases. Historically, the modification of the glycosyl unit has focused on the 2'-, 3'-, and 4'-positions as well as the ribofuranosyl ring oxygen. By contrast, the 1'-position has rarely been studied due to the labile nature of the anomeric position. However, the improved chemical stability of C-nucleosides allows the modification of the 1'-position with substituents not found in conventional N-nucleosides. Herein, we disclose new chemistry for the installation of diverse substituents at the 1'-position of C-nucleosides, including alkyl, alkenyl, difluoromethyl, and fluoromethyl substituents, using the 4-amino-7-(1'-hydroxy-d-ribofuranosyl)pyrrolo[2,1-f][1,2,4]triazine scaffold as a representative purine nucleoside mimetic.

Molecular Mechanism Exploration of Potent Fluorinated PI3K Inhibitors with a Triazine Scaffold: Unveiling the Unusual Synergistic Effect of Pyridine-to-Pyrimidine Ring Interconversion and CF3 Defluorination.

The phosphatidylinostitol-3-kinase (PI3K)/AKT/mammalian target of rapamycin signaling pathway is a vital regulator of cell proliferation, growth, and survival, which is frequently overactivated in many human cancers. To this effect, PI3K, which is an important mediator of this pathway, has been pinpointed as a crucial target in cancer therapy and hence the importance of PI3K inhibitors. It was recently reported that defluorination and pyridine-to-pyrimidine ring interconversion increase the potency of specific small-molecule inhibitors of PI3K. Compound 4, an inhibitor with the difluorinated pyrimidine motif, was found to be eight times more potent against PI3K than compound 1, an inhibitor with the trifluorinated pyridine motif. This observation presents the need to rationally resolve the differential inhibitory mechanisms exhibited by both compounds. In this present work, we employed multiple computational approaches to investigate and distinguish the binding modes of 1 and 4 in addition to the effects they mediate on the secondary structure of PI3K. Likewise, we evaluated two other derivatives, compounds 2 with the difluorinated pyridine motif and 3 with the trifluorinated pyrimidine motif, to investigate the cooperativity effect between the defluorination of CF3 and pyridine-to-pyrimidine ring interconversion. Findings revealed that PI3K, upon interaction with 4, exhibited a series of structural changes that favored the binding of the inhibitor at the active-site region. Furthermore, a positive (synergistic) cooperativity effect was observed between CF3 defluorination and pyridine-to-pyrimidine ring interconversion. Moreover, there was a good correlation between the binding free energy estimated and the biological activity reported experimentally. Energy decomposition analysis revealed that the major contributing force to binding affinity variations between 1 and 4 is the electrostatic energy. Per-residue energy-based hierarchical clustering analysis further identified four hot-spot residues ASP841, TYR867, ASP964, and LYS833 and four warm-spot residues ASP836, SER806, ASP837, and LYS808, which essentially mediate the optimal and higher-affinity binding of compound 4 to PI3K relative to 1. This study therefore provides rational insights into the mechanisms by which 4 exhibited superior PI3K-inhibitory activities over 1, which is vital for future structure-based drug discovery efforts in PI3K targeting.

Developing novel classes of protein kinase CK1δ inhibitors by fusing [1,2,4]triazole with different bicyclic heteroaromatic systems.

Protein kinase CK1δ expression and activity is involved in different pathological situations that include neuroinflammatory and neurodegenerative diseases. For this reason, protein kinase CK1δ has become a possible therapeutic target for these conditions. 5,6-fused bicyclic heteroaromatic systems that resemble adenine of ATP represent optimal scaffolds for the development of a new class of ATP competitive CK1δ inhibitors. In particular, a new series of [1,2,4]triazolo[1,5-c]pyrimidines and [1,2,4]triazolo[1,5-a][1,3,5]triazines was developed. Some crucial interactors have been identified, such as the presence of a free amino group able to interact with the residues of the hinge region at the 5- and 7- positions of the [1,2,4]triazolo[1,5-c]pyrimidine and [1,2,4]triazolo[1,5-a][1,3,5]triazine scaffolds, respectively; or the presence of a 3-hydroxyphenyl or 3,5-dihydroxyphenyl moiety at the 2- position of both nuclei. Molecular modeling studies identified the key interactions involved in the inhibitor-protein recognition process that appropriately fit with the outlined structure-activity relationship. Considering the fact that the CK1 protein kinase is involved in various pathologies in particular of the central nervous system, the interest in the development of new inhibitors permeable to the blood-brain barrier represents today an important goal in the pharmaceutical field. The best potent compound of the series is the 5-(7-amino-5-(benzylamino)-[1,2,4]triazolo[1,5-a][1,3,5]triazin-2-yl)benzen-1,3-diol (compound 51, IC50=0.18μM) that was predicted to have an intermediate ability to cross the membrane in our invitro assay and represents an optimal starting point to both studies the therapeutic value of protein kinase CK1δ inhibition and to develop new more potent derivatives.

Recent Advances on the s‐Triazine Scaffold with Emphasis on Synthesis, Structure‐Activity and Pharmacological Aspects: A Concise Review

AbstractTriazine nuclei have occupied a propitious place in pharmaceutical chemistry due to their diverse biological behaviour. The marketed drugs such as Azacitidine, Melarsoprol, Altretamine and Almitrine display broad pharmacological activities like anti‐cancer, anti‐parasitic, anti‐inflammatory, Respiratory stimulant and many more. Literature studies reveal that the 2, 4, and 6 substitution on s‐triazine is important for varied biological activities. This diversity in pharmacological activities of triazine scaffold has fascinated the various researchers to further investigate its applications in the treatment of several diseases. This review is complementary to earlier reports and aims to review the work reported on various synthetic methods and biological activities of substituted s‐triazine derivatives from 2016 to 2020 with a list of patents. The enriched structure‐activity relationship may open the doors for further rational drug development of s‐triazine containing analogues as good clinical candidates.

Multifunctional Neomycin-Triazine-Based Cationic Lipids for Gene Delivery with Antibacterial Properties.

Cationic lipids (CLs) have gained significant attention among nonviral gene delivery vectors due to their ease of synthesis and functionalization with multivalent moieties. In particular, there is an increasing request for multifunctional CLs having gene delivery capacity and antibacterial activity. Herein, we describe the design and synthesis of a novel class of aminoglycoside (AG)-based multifunctional vectors with high transfection efficiency and noticeable antibacterial properties. Specifically, cationic amphiphiles were built on a triazine scaffold, allowing for an easy derivatization with up to three potentially different substituents, such as neomycin (Neo) that serves as the polar head and one or two lipophilic tails, namely stearyl (ST) and oleyl (OL) alkyl chains and cholesteryl (Chol) tail. With the aim to shed more light on the effect of different types and numbers of lipophilic moieties on the ability of CLs to condense and transfect cells, the performance of Neo–triazine-based derivatives as gene delivery vectors was evaluated and compared. The ability of Neo–triazine-based derivatives to act as antimicrobial agents was evaluated as well. Neo–triazine-based CLs invariably exhibited excellent DNA condensation ability, even at a low charge ratio (CR, +/−). Besides, each derivative showed very good transfection performance at its optimal CR on two different cell lines, along with negligible cytotoxicity. CLs bearing symmetric two-tailed OL proved to be the most effective in transfection. Interestingly, Neo–triazine-based derivatives, used as either free lipids or lipoplexes, exhibited strong antibacterial activity against Gram-negative bacteria, especially in the case of CLs bearing one or two aliphatic chains. Altogether, these results highlight the potential of Neo–triazine-based derivatives as effective multifunctional nonviral gene delivery vectors.

Biomimetic Affinity Ligands for Protein Purification.

The development of sophisticated molecular modeling software and new bioinformatic tools, as well as the emergence of data banks containing detailed information about a huge number of proteins, enabled the de novo intelligent design of synthetic affinity ligands. Such synthetic compounds can be tailored to mimic natural biological recognition motifs or to interact with key surface-exposed residues on target proteins, and are designated as "biomimetic ligands". A well-established methodology for generating biomimetic or synthetic affinity ligands integrates rational design with combinatorial solid-phase synthesis and screening, using the triazine scaffold and analogs of amino acid side chains to create molecular diversity.Triazine-based synthetic ligands are nontoxic, low-cost, and highly stable compounds that can replace advantageously natural biological ligands in the purification of proteins by affinity-based methodologies.

Synthetic Ligand Affinity Chromatography Purification of Human Serum Albumin and Related Fusion Proteins.

Synthetic ligand affinity adsorbents offer an efficient means for purification of biopharmaceuticals. Single-isomer textile dye C.I. Reactive Blue and newer ligands developed by rational design and screening of chemical combinatorial libraries based on a triazine scaffold are routinely used for the capture and purification of these proteins from engineered recombinant expression systems. Here, we describe methods for the purification of recombinant human serum albumin and related fusion proteins using synthetic ligand affinity adsorbents.

DNA interaction analysis with automated biosensor of paraben derivative s-triazines

Among all heterocyclic compounds, the triazine scaffold has an important place due to its wide range of biological activities. Triazine has been preferred by many researchers as the target structure for the design and development of new drugs, as it is found in many biologically active molecules with promising biological potential such as anti-inflammatory, anti-mycobacterial, anti-viral, anti-cancer properties. In this study, a series of paraben substituted s-triazine compounds 1-5 were synthesized and their structures were determined by 1H and 13C NMR spectroscopies as well as mass spectrometry. Also, structure of compound 5 was adjusted by X-ray crystallographic technique and crystallographic analysis revealed that 5 was crystallized in the trigonal space group R-3. According to X-ray analysis, compound 5 has very important intermolecular interaction such as nonclassical H-bond and pi-pi interaction. These interactions lead formation of supramolecular network. The thermal stabilities were investigated by thermogravimetric analysis. According to thermogravimetric analysis results, all of the synthesized compounds have high thermal stability. DNA interaction studies of the compounds 1-5 were performed with an automatic biosensor device that can measure the efficiency of DNA hybridization on the biochip surface. The biosensor results show that benzyl paraben substituted s-triazine compound 5, the most reactive compound at low concentration, was showed 61% and 75% activity reduction at concentrations 12.5 and 25 µM.

Discovery of potent and highly selective covalent inhibitors of Bruton’s tyrosine kinase bearing triazine scaffold

Bruton’s tyrosine kinase (BTK), as a key regulator of the B cell receptor (BCR) signaling pathway, is an attractive therapeutic target for the treatment of various diseases such as leukemia and B-cell malignancies. Herein, a series of compounds bearing 1, 3, 5-triazine core were prepared, and their biological activities on BTK were determined. Then the molecular docking study and ADME property prediction were made and a highly potent selective BTK inhibitor B8 (IC50 = 21.0 nM) was discovered. Compound B8 exhibited excellent activity with 5.14 nM inhibition of Raji cells and 6.14 nM inhibition of Ramos cells respectively. Additionally, B8 potently inhibited BTK kinase Y223 auto-phosphorylation, arrested cell cycle in G2/M phase and induced apoptosis in Ramos cells. The high selectivity for BTK and high potency in TMD8 cells of B8 suggested a low risk of off-target related adverse effects. Further molecular docking and dynamic simulation on B8 furnished insights into its binding profile within BTK. With significant efficacy in cellular assays and good ADME and safety profiles, B8 can be identified as a promising BTK inhibitor worthy of further profiling.